

A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT Reduction of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease

NCT05427786

Status	RECRUITING
Phase	Phase 4
Sponsor	Korea University Anam Hospital
Enrollment	460 participants

Key Eligibility Criteria

Inclusion (3)

- Over 19 years old
- Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information
- Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease

Exclusion (6)

- Patients with TIMI d 2 before coronary intervention
- Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
- Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
- Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration
- Those whose surviving life is expected to be less than 1 year
- ... and 1 more (see full listing online)

Locations (1 total)

Korea University Anam Hospital, Seoul, South Korea